The EPS projection of NeoGenomics, Inc. (NASDAQ:NEO) for quarter ended 2016-09-30 is $0.02. Last week, the EPS forecast was $0.02 against target of $0.02, a month earlier. Two months ago, this estimate was $0.02 versus forecast of $0.02 three months earlier, implying a deviation of 0%.
NeoGenomics, Inc. (NASDAQ:NEO) stated that 18 days ago, its stock price was positively revised 0 times while negative revisions were 0.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 1, 3, and 3, correspondingly.
EPS estimate downgrade for NeoGenomics, Inc. (NASDAQ:NEO) in the preceding 30, 120, 60 and 90 days were 0, 0, 0, and 0, correspondingly.
NeoGenomics, Inc. (NASDAQ:NEO) EPS target for the quarter closed 1 was $0.02, based on 3 recommendations. As reported on 2016-04-27 the EPS was $0.04. The change was $0.14, implying a percentage deviation of 140%. The projections showed a standard deviation of 0.03.
Quarterly Sales Estimates
NeoGenomics, Inc. (NASDAQ:NEO) yearly sales prediction for the fiscal 2016 stands at $64.943 and the median estimate is at $64.935. Almost 4 analysts issued sales target.
Highest sales target is $66.1 while the lowest target is $63.802 showing standard deviation of 1.041%.
As many as 4 analysts have sales targets revised upside while 4 reduced sales estimates, implying a deviation of 0%.
Last month, 4 revised sales number projection on upside while 4 lowered the sales projections, implying a deviation of 0%.
A quarter ago, 4 hiked sales target and 4 reduced sales forecast. NeoGenomics, Inc. (NASDAQ:NEO) announced that the deviation in forecast was -1.201%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...